What Happened?
Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 5.8% in the afternoon session after genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems.
Under the agreement, Sampled will perform genomics analyses for the Million Veteran Program. Sampled is one of the largest U.S. users of the PacBio Revio platform and deploys multiple PacBio Revio long-read sequencing systems to provide high-throughput sequencing workflows.
The shares closed the day at $1.72, up 7.9% from the previous close.
Is now the time to buy PacBio? Access our full analysis report here, it’s free.
What Is The Market Telling Us
PacBio’s shares are extremely volatile and have had 84 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 11 months ago when the stock gained 17.9% on the news that its positive momentum continued as it was disclosed that Cathie Wood's investment firm, ARK Invest, purchased more than one million of the company's shares. The firm's ARKK fund acquired 1,028,318 shares, a stake valued at approximately $2,025,786. The move from the well-known, innovation-focused investor signaled strong confidence in the genomics company. This purchase was also consistent with ARK's buying pattern of PacBio stock over the preceding week, highlighting the firm's continued positive view of the sector.
PacBio is down 6.8% since the beginning of the year, and at $1.72 per share, it is trading 35.8% below its 52-week high of $2.67 from January 2026. Investors who bought $1,000 worth of PacBio’s shares 5 years ago would now be looking at only $68.96.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.